| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.8 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.009 | 0.8 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |